Zacks: Analysts Anticipate McKesson Co. (MCK) Will Post Quarterly Sales of $53.43 Billion
Brokerages predict that McKesson Co. (NYSE:MCK) will announce $53.43 billion in sales for the current quarter, Zacks reports. Five analysts have made estimates for McKesson’s earnings, with the lowest sales estimate coming in at $52.87 billion and the highest estimate coming in at $53.78 billion. McKesson posted sales of $51.63 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 3.5%. The firm is scheduled to announce its next earnings results on Thursday, May 23rd.
On average, analysts expect that McKesson will report full-year sales of $215.02 billion for the current fiscal year, with estimates ranging from $214.07 billion to $215.67 billion. For the next year, analysts anticipate that the firm will post sales of $223.15 billion, with estimates ranging from $216.19 billion to $227.85 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow McKesson.
McKesson (NYSE:MCK) last posted its quarterly earnings data on Thursday, January 31st. The company reported $3.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $3.18 by $0.22. McKesson had a negative net margin of 0.15% and a positive return on equity of 27.83%. The business had revenue of $56.21 billion during the quarter, compared to analysts’ expectations of $55.27 billion. During the same quarter in the prior year, the business posted $3.41 earnings per share.
In other McKesson news, EVP Lori A. Schechter sold 7,700 shares of the business’s stock in a transaction dated Wednesday, January 16th. The stock was sold at an average price of $122.96, for a total transaction of $946,792.00. Following the completion of the transaction, the executive vice president now owns 10,000 shares of the company’s stock, valued at $1,229,600. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.87% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of MCK. Proficio Capital Partners LLC increased its stake in shares of McKesson by 161.2% in the fourth quarter. Proficio Capital Partners LLC now owns 222 shares of the company’s stock valued at $25,000 after buying an additional 137 shares during the period. Bedel Financial Consulting Inc. increased its stake in shares of McKesson by 165.2% in the fourth quarter. Bedel Financial Consulting Inc. now owns 236 shares of the company’s stock valued at $26,000 after buying an additional 147 shares during the period. Old North State Trust LLC increased its stake in shares of McKesson by 53.3% in the fourth quarter. Old North State Trust LLC now owns 391 shares of the company’s stock valued at $43,000 after buying an additional 136 shares during the period. IMS Capital Management acquired a new position in shares of McKesson in the third quarter valued at approximately $57,000. Finally, Financial Gravity Companies Inc. acquired a new position in shares of McKesson in the fourth quarter valued at approximately $57,000. 91.31% of the stock is owned by hedge funds and other institutional investors.
MCK traded up $1.17 on Monday, hitting $135.56. 1,072,244 shares of the stock were exchanged, compared to its average volume of 1,705,008. McKesson has a 12 month low of $106.11 and a 12 month high of $160.87. The company has a quick ratio of 0.57, a current ratio of 1.02 and a debt-to-equity ratio of 0.81. The stock has a market capitalization of $26.00 billion, a price-to-earnings ratio of 10.74, a P/E/G ratio of 1.40 and a beta of 1.25.
The firm also recently announced a quarterly dividend, which will be paid on Monday, April 1st. Shareholders of record on Friday, March 1st will be paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 1.15%. The ex-dividend date of this dividend is Thursday, February 28th. McKesson’s payout ratio is 12.36%.
McKesson Company Profile
McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.
Further Reading: How Does the Quiet Period Work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.